Uni Pharma (6621) has laid out the pet cancer screening market, and joined hands with the research team of Professor Lin Chenqi of the Department of Veterinary Medicine of National Taiwan University to develop its own tumor marker DR70, and achieved important research and development results, and appeared at the annual forum of the American College of Veterinary Internal Medicine (ACVIM American College of Veterinary Internal Medicine) this month (June), which is expected to change the clinical screening and post-treatment tracking guidelines for pet cancer treatment.
Uni Pharma’s tumor marker DR70, after being treated with a patented formula, has been successfully confirmed to be able to detect the tumor marker DR70 in the blood of dogs with cancer, so as to distinguish dogs with cancer, and has excellent potential for clinical screening of pet cancer.
DR-70 was approved by the US FDA in 2008 for postoperative adjuvant surveillance of human colorectal cancer. The latest research results published by the research team of the Department of Veterinary Medicine of National Taiwan University also found that the use of DR-70 for auxiliary monitoring after canine cancer treatment has the same results, and the level of DR-70 is positively correlated with cancer recurrence and treatment effectiveness after treatment, and these research results were also published at the American College of Veterinary Medicine (ACVIM) Annual Forum this month.
ACVIM is the world’s largest professional organization for veterinary medicine, and since 1983, it has hosted an annual forum to present the latest research findings and provide veterinarians with state-of-the-art information. The results of this study prove that DR-70 can be used not only as a powerful tool for cancer risk detection, but also as an important tool to assist in the evaluation of treatment effectiveness.
Original news: https://ctee.com.tw/livenews/aj/ctee/A88131002022062818264983
